Introduction {#S1}
============

Schistosomiasis is a disease caused by trematode worms of the genus *Schistosoma* that affects about 207 million people in 76 countries worldwide ([@B1], [@B2]). The main treatment of schistosomiasis is currently the use of anthelmintic drugs, being praziquantel (PZQ) the most widely drug used in chemotherapy. The treatment, although effective, is facing some limitations because the chemotherapy is active only against adult forms of the parasite (not acting on the larval form) and mass treatment does not prevent reinfection ([@B3]--[@B5]). The lack of new therapeutic drugs and preventive measures, as well as the high disease burden caused by the reinfection are justifications for developing a vaccine against schistosomiasis ([@B4]).

Many efforts have been accomplished for the development of an effective vaccine against schistosomiasis ([@B4], [@B6]). Most of the important vaccine targets described up to date are proteins located at the parasite/host interface, since they are commonly associated with mechanisms of escape from the host immune system or other adaptation to parasitism ([@B7]) and the two major interfaces are the outer tegument and the gastrodermis ([@B6], [@B8]).

In order to characterize new targets for vaccine development, we decided to perform a pre-clinical study using the recombinant protein *Sm*KI-1. This protein is a Kunitz-type protease inhibitor (KI) recently characterized as an inhibitor for some serine proteases, with possible important functions in anti-coagulation processes ([@B9]) and in the parasite immune evasion, through the blockage of neutrophil recruitment ([@B10]). In this study, our main goal is to evaluate the vaccine potential of recombinant (r)*Sm*KI-1, and its two fragments: KI domain and C-terminal region, since bioinformatic analysis predicts relevant epitope differences between the KI domain and C-terminal tail. Aiming to test such prediction, we performed vaccination experiments in mice with the whole recombinant protein and its fragments and evaluated the production of specific antibodies, cytokines, and the protection efficacy against schistosomiasis. Our data revealed that vaccination with whole recombinant SmKI-1 (rSmKI-1) and its C-terminal tail, but not its KI domain, induced reduction in worm burden and liver pathology in immunized mice.

Materials and Methods {#S2}
=====================

Ethics Statement {#S2-1}
----------------

All experiments involving animals were conducted in accordance with the Brazilian Federal Law number 11,794, which regulates the scientific use of animals in Brazil, the Institutional Animal Care and Use Committees guidelines and the Animal Welfare Act and Regulations guidelines established by the American Veterinary Medical Association Panel on Euthanasia. Animals were fed, housed, and handled in strict agreement with these recommendations. All protocols were approved by the Committee for Ethics in Animal Experimentation (CETEA) at Universidade Federal de Minas Gerais (UFMG) under permit \#185/2017.

Mice and Parasites {#S2-2}
------------------

Female C57BL/6 mice aged 6--8 weeks were purchased from the UFMG animal facility. The number of mice used in each individual experiment was calculated taking into account a significance of 0.1%, a test power of 95%, and differences and SDs based on previous literature ([@B11], [@B12]). The number of mice demanded to calculate vaccine efficacy (*n* = 10), or cytokine production (*n* = 5), or antibody titers (*n* = 10), or liver analyses (*n* = 8) were approved by the CETEA at Universidade Federal de Minas Gerais (UFMG) under permit \#185/2017. *Schistosoma mansoni* (LE strain) cercariae were routinely maintained in *Biomphalaria glabrata* snails at "Centro de Pesquisa René Rachou Fiocruz (CPqRR)" and prepared by exposing infected snails to light for 2 h to induce shedding of parasites. Cercariae numbers and viability were determined, prior to infection, using a light microscope. Schistosomula were obtained after separation from the tails by centrifugation using a 57% Percoll (Pharmacia, Uppsala, Sweden) solution. Parasites were cultured for at least 7 days *in vitro* as previously described ([@B13]).

Chemicals {#S2-3}
---------

All reagents were purchased from Sigma-Aldrich, Co. (St. Louis, MO, USA) unless otherwise specified.

Accession Number {#S2-4}
----------------

*Sm*KI-1 (Smp_147730) CCD77156.1.

Determination of Potential Epitopes for *Sm*KI-1 Antigen {#S2-5}
--------------------------------------------------------

MHC binding was predicted using neural network (NN) ensembles trained to the LN ic50 ([@B14]) for over 200,000 binding reactions using the neural platform of JMP^®^ (SAS Institute). This is an updated version of a prediction system described previously ([@B15]). Predicted MHC binding affinity was computed for each sequential 9-mer and 15-mer peptide in the protein for 37 MHC-I and 28 MHC-II alleles, including 16 DRB alleles. Binding affinities to inbred murine alleles were similarly determined. To estimate population behavior comprising multiple alleles with varying affinities for any peptide, the LN ic50 binding data estimates were transformed and standardized to a zero mean unit variance within each protein using a Johnson Sb distribution ([@B16]). To compute a permuted average across human alleles, the highest predicted binding affinity at each peptide position was determined for every possible haplotype pairing and averaged. B cell linear epitopes were predicted as previously described ([@B17]) based on NN predictions trained and cross-validated on the output of a large random peptide set submitted to BepiPred 1.0 ([@B18]). The NN provides a structurally based predictor of the probability that an amino acid (within a window ± 4 amino acids) is on the outside of a protein and a likely contact point for a binding antibody based on the biophysical properties of each peptide. The probability of cleavage of each protein by human cathepsin B, L, or S was determined. Both binding affinity and cleavage predictions were accomplished using previously described methods by NN predictors based on principal component analysis of amino acid physical properties ([@B17]). T cell exposed motif patterns were extracted from the complete proteomes and ranked as previously described for each of three amino acid recognition patterns which engage T cell receptors ([@B15], [@B19]). Frequencies of motif occurrence were determined with respect to the human immunoglobulinome, based on a data set of over 40 million immunoglobulin variable regions, the human proteome, and the gastrointestinal microbiome ([@B20]). To identify potentially suppressive motifs, very common T cell exposed motifs with high binding affinity, or the absence thereof, were identified.

Synthesis of Recombinant Proteins {#S2-6}
---------------------------------

The recombinant protein r*Sm*KI-1 and its fragments, Kunitz (KI) domain (N-terminal Arg^22^--Thr^82^) and C-terminal tail (C-terminal Gli^79^--Glu^146^), were produced as previously described ([@B10]). Briefly, plasmids containing the sequence for r*Sm*KI-1 or KI-domain or C-terminal tail from SmKI-1 were transformed into *E. coli* Rosetta™ (Merck KGaA, Darmstadt, Germany) competent cells. Cells transformed were cultured in selective medium and gene expression was induced by 1 mM isopropylthiogalactoside (IPTG). After induction, the bacterial cells were harvested and recombinant proteins were recovered as inclusion bodies and solubilized. Each protein was purified by affinity chromatography on a Ni-Sepharose column (Hitrap chelating 5 mL) using an AKTA prime Plus chromatography system (GE Healthcare, São Paulo, Brazil) according to the manufacturer's protocol. Fractions containing proteins used in this study were determined through SDS/PAGE-20% and then, dialyzed against PBS pH 7.0. The recombinant proteins were quantified using the BCA kit (Pierce, Waltham, MA, USA). To evaluate the amount of endotoxin present, the samples were submitted to Limulus Amebocyte Lysate QCL-1000™ (Lonza) assay. Protein samples show less than 1 endotoxin unit (EU)/mg.

SDS-PAGE and Immunoblotting {#S2-7}
---------------------------

Purified r*Sm*KI-1 and its fragments were analyzed on prepared 12% polyacrylamide SDS-PAGE gels and run as previously described ([@B21]). Proteins were then transferred to a Hybond-P PVDF membrane (GE Healthcare, Pittsburgh, PA, USA) ([@B22]). The membrane was blocked with TBS-T (tris-buffered saline pH 7.5, 0.05% Tween 20) containing 5% dry non-fat milk powder for 16 h at 4°C. The membrane was then incubated with mouse polyclonal antibodies to r*Sm*KI-1, or KI domain, or C-terminal (diluted 1:100) for 1 h at room temperature. After three washes with TBS-T, the membrane was incubated with goat anti-mouse IgG conjugated to horseradish peroxidase (HRP) (1:2,000) for 1 h at room temperature. After three washes, the membranes were developed using Immobilion™ Western HRP subtract (Millipore Corporation, Billerica, MA, USA) according to the manufacturer's instructions and visualized in Amersham Imager 600 (GE Healthcare).

Immunolocalization of *Sm*KI-1 in *S. mansoni* Schistosomula {#S2-8}
------------------------------------------------------------

To immunolocalize *Sm*KI-1, 7-day cultured schistosomula were prepared *in vitro* as described ([@B23]). A whole-mount protocol was used, comprising of parasites fixed with −20°C pure acetone for 15 min and washed with saline. Then, schistosomula were blocked with 1% bovine serum albumin (BSA) in phosphate buffered saline (PBST pH 7.2, 0.05% Tween-20) for 1 h. The samples were incubated with anti-r*Sm*KI-1 serum diluted 1:25 in blocking buffer for 1 h. Serum from non-immunized mice was used, in the same dilution, as a negative control. The samples were washed with PBST and incubated with an anti-mouse IgG antibody conjugated to FITC (Molecular Probes, Carlsbad, CA, USA) diluted 1:100 in blocking buffer. Finally, samples were washed, mounted, and viewed using a Nikon Eclipse Ti fluorescence microscope from the "Centro de Aquisição e Processamento de Imagens (CAPI-ICB/UFMG)."

Mice Immunization, Challenge Infection, and Parasite Burden Assessment {#S2-9}
----------------------------------------------------------------------

Six- to eight-week-old female C57BL/6 mice were divided into four groups of ten mice each. Mice received vaccine formulation subcutaneously, at the nape of the neck. Each vaccine was prepared with 25 µg of proteins (r*Sm*KI-1, KI domain, or C-terminal) or with a similar volume of PBS (Adjuvant Control Group, ACG), on days 7, 22, and 37, as described in Figure S1A in Supplementary Material. All vaccine preparations, including the negative control (ACG), were formulated using Complete Freund's Adjuvant (CFA) for the first immunization and Incomplete Freund's Adjuvant (IFA) for the following two immunizations (Sigma-Aldrich, Co., St. Louis, MO, USA). Fifteen days after the final immunization, mice were anesthetized with 5% ketamine, 2% xylazine, and 0.9% NaCl and challenged with 100 cercariae (LE strain) through percutaneous exposure of the abdominal skin for 1 h. Forty-five days after challenge, adult worms were perfused from the portal veins of each animal and counted as described previously ([@B24]). The protection level was calculated by comparing the recovered total worm number, total female number, and total male number from each group in relation to the control group. Two independent experiments were performed.

Measurement of Specific Antibodies {#S2-10}
----------------------------------

Following immunization, sera were collected from mice in each experimental group at 2 week intervals. The levels of specific anti-r*Sm*KI-1, anti-KI domain, or anti-C-terminal antibodies were measured by indirect ELISA, as previously described ([@B25]). Maxisorp 96-well microtiter plates were coated with 5 µg/mL of each protein in carbonate-bicarbonate buffer (pH 9.6) and then blocked for 2 h at room temperature with PBST (phosphate buffer saline, pH 7.2 with 0.05% Tween-20) plus 10% FBS (fetal bovine serum). Diluted serum (1:100) was added to each well, and plates were then incubated at room temperature. For antibody specificity tests, only samples collected at day 45 (last bleed before cercariae challenge) were used. For each serum, 20 dilutions were evaluated (starting at 1:20 and following a twofold serial dilution). Each dilution was added per well, and plates were then incubated at room temperature. The titer of each sample corresponds to the highest dilution factor that still yields a positive reading, which is the optical density (OD) of 0.010. Titers were expressed by their denominators. Plate-bound antibodies were detected using peroxidase-conjugated anti-mouse IgG, IgG1, or IgG2c (Southern Biotechnology, CA, USA) diluted 1:5,000, 1:10,000, and 1:2,000, respectively. Color reaction was induced by adding OPD (o-phenylenediamine) in citrate buffer (pH 5.0) plus H~2~O~2~ to each well. The color reaction was stopped by adding 5% sulfuric acid to each well. The plates were read at 492 nm in an ELISA plate reader (BioRad, Hercules, CA, USA).

Cytokine Analysis in Cell Supernatants {#S2-11}
--------------------------------------

The cytokine experiments were performed using cultured splenocytes from individual C57BL/6 mice immunized three times with r*Sm*KI-1, KI domain, C-terminal, or PBS (ACG) (*n* = 5/group). Ten days after the final immunization, mice were euthanized and spleens were collected for further analysis. The cytokine analysis protocol is demonstrated in Figure S1B in Supplementary Material. The splenocytes were maintained in culture with medium alone or stimulated with 5 µg/mL of proteins r*Sm*KI-1, KI domain, or C-terminal. For positive controls, cells were stimulated with either concanavalin A (ConA) (5 µg/mL) or lipopolysaccharide (LPS) (1 µg/mL), as previously described ([@B24]). Culture supernatants were collected after 24 h to measure IL-4 and IL-5 levels, after 48 h to measure TNF-α levels, and after 72 h to measure IFN-γ and IL-10 levels. Cytokine measurement assays were performed using the DuoSet ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.

Egg Counts {#S2-12}
----------

To evaluate the effect of immunization with r*Sm*KI-1 or its fragments on liver pathology, livers from eight mice per group were collected following perfusion for worm recovery. Liver fragments from each animal were weighed and digested with 10% KOH at 37°C. Released eggs were obtained by centrifugation at 900 *g* for 10 min and resuspended in 1 mL of saline. Egg numbers were counted using a light microscope. Quantification was obtained by calculating the number of eggs per gram of liver tissue.

Histopathological Analysis {#S2-13}
--------------------------

Liver samples taken from the central part of the left lateral lobe were fixed with 10% buffered formaldehyde in PBS. Histological sections were performed using microtome at 6 µm and stained on a slide with haematoxylin-eosin (HE). For measurement of granuloma area, a microscope with 10× objective lens was used and images were obtained through a JVC TK-1270/RBG microcamera attached to the microscope. Twenty granulomas, containing a single well-defined egg were randomly selected in each liver section and the granuloma area was measured using the ImageJ software (U.S. National Institutes of Health, Bethesda, MD, USA, <http://rsbweb.nih.gov/ij/index.html>).

Statistical Analysis {#S2-14}
--------------------

Cytokine and antibody analysis were performed using two-way ANOVA and Bonferroni adjustments for comparisons between groups. The results from vaccination experiment (worm burden, egg count, and histopathology) were compared by paired Student's *t-test*. The *p*-values obtained were considered significant if they were \<0.05. Statistical analysis was performed using GraphPad Prism 6 (La Jolla, CA, USA).

Results {#S3}
=======

*S. mansoni Sm*KI-1 Epitope Mapping {#S3-1}
-----------------------------------

Mapping of predicted B and T cell epitopes indicates that the most probable B cell epitopes are located in the region of amino acids 89--116 (Figure [1](#F1){ref-type="fig"}). In this region there are also peptides predicted to have a high affinity binding for many human MHC II DRB alleles, and for murine H2-I-A^b^. Many of the predicted high binding peptides are also predicted to be excised by cathepsins. In contrast the Kunitz domain is lacking in strong B cell epitopes, although it has many peptides with predicted human DRB high affinity binding and some 15-mer peptides predicted to bind to H2-I-A^b^. This indicates that the C-terminal half of the protein is most likely to elicit a strong antibody response.

![*Sm*KI-1 epitope mapping. **(A)** Representation of the overall epitope mapping of *Sm*KI-1 as presented to a human host. *X* axis indicates sequential peptides with single amino acid displacement. *Y* axis indicates predicted binding affinity in SD units for the protein. Blue lines represent the permuted average of predicted binding of 16 human DRB, in the 15-mer starting at that index position. Red lines indicate the permuted average of predicted binding of 37 human HLA-A and HLA B alleles, in the 9-mer starting at that index position. Blue and red bars across the base line indicate the top 10% of predicted binding peptides. Orange bars indicate probability of a linear B cell epitope starting at that peptide index position. White background indicates signal peptide; yellow the secreted protein. **(B)** Predicted MHC II binding for C57BL/6 H-2-IA^b^ alleles for sequential 15-mer peptides (blue), hashed bars show the peptides predicted to be excised by cathepsin B, L, or S, and probability of B cell linear epitopes (orange). The *Y* axis units for MHC binding are SD units below the mean of the natural log binding affinity (lnIC~50~) for that protein; and the SD of linear B cell epitope probability (inverted).](fimmu-09-01762-g001){#F1}

*Sm*KI-1 Is Localized on the Surface of the Intestinal Tract of Schistosomula {#S3-2}
-----------------------------------------------------------------------------

In a recent study, *Sm*KI-1 was found on the tegument of adult males and females ([@B9]). However, there is no information about *Sm*KI-1 localization in schistosomula. Therefore, we stained whole 7-day cultured schistosomula with mouse polyclonal antibodies raised against r*Sm*KI-1 to localize this protein in the larval stage of the parasite. The native *Sm*KI-1 protein (green) was located exclusively in the posterior portion of gut lumen, possibly in the syncytial surface of the gastrodermis of *S. mansoni* schistosomula (Figure [2](#F2){ref-type="fig"}A). No specific fluorescent signal was detected in the gut or elsewhere when serum from naïve mice (pre-serum) was used in schistosomula from the same source (Figure [2](#F2){ref-type="fig"}B).

![Immunolocalization of *Sm*KI-1 in whole 7-day schistosomula. **(A)** Indirect immunofluorescent labeling of native *Sm*KI-1 in whole fixed schistosomula using mouse polyclonal anti-recombinant SmKI-1 and a secondary anti-mouse conjugated to FITC (green). Arrows indicate clear intestinal staining. **(B)** As a control, serum from naive mice was used.](fimmu-09-01762-g002){#F2}

Vaccination With *Sm*KI-1 and Its Fragments Induces High-Specific IgG Titers {#S3-3}
----------------------------------------------------------------------------

Recombinant *Sm*KI-1 was produced and tested as a vaccine candidate against schistosomiasis. Since bioinformatic analysis pointed to relevant differences between the KI domain and C-terminal tail, each fragment of *Sm*KI-1 was also tested individually. C57BL/6 mice were immunized with 3 doses of each vaccine formulated as 25 µg of each protein (r*Sm*KI-1, KI domain, or C-terminal), or PBS (ACG) in Freund's adjuvant (CFA/IFA). Sera from 10 animals from each vaccination group were tested by ELISA to evaluate the levels of specific total IgG or IgG subclasses (IgG1 and IgG2c) antibodies to r*Sm*KI-1, KI domain, or C-terminal. From day 30 onward, all groups immunized with the whole protein or its fragments were able to produce higher levels of specific IgG antibodies in comparison to ACG (Figure [3](#F3){ref-type="fig"}A). All mice vaccinated with r*Sm*KI-1, KI domain and C-terminal, produced significant titers of specific IgG antibodies compared with the control group vaccinated with PBS (ACG) at day 45, pre-challenge with cercariae, and at day 90, before euthanasia as demonstrated in Figure S2 in Supplementary Material. No differences were found among mice which received SmKI-1, KI-domain, or C-terminal antigens. The measurement of IgG isotypes revealed that immunization induced the production of antigen-specific IgG1 (Figure [3](#F3){ref-type="fig"}B) and IgG2c (Figure [3](#F3){ref-type="fig"}C) after the second injection. When compared to mice immunized with SmKI-1, KI-domain-immunized animals produced lower levels of both IgG1 and IgG2c. Antibody binding to recombinant proteins was investigated using two different methodologies, ELISA (Figure [3](#F3){ref-type="fig"}D) and Western blot (Figure [3](#F3){ref-type="fig"}E). In both experiments, only 45-day serum was used. For ELISA, plates were first coated with r*Sm*KI-1, KI domain, or C-terminal and serum from immunized mice (20 dilutions each) was then added to each well. The data show that antibodies from mice immunized with rSmKI-1, KI domain or C-terminal are able to bind to the whole rSmKI-1 (Figure [3](#F3){ref-type="fig"}D---top bars). Anti-KI domain antibodies recognize mostly r*Sm*KI-1 and KI domain (Figure [3](#F3){ref-type="fig"}D---middle bars), while anti-C-terminal antibodies recognize predominantly r*Sm*KI-1 and C-terminal fragment (Figure [3](#F3){ref-type="fig"}D---bottom bars). For Western blot analysis, purified rSmKI-1 as well as KI domain and C-terminal were resolved by SDS-PAGE (Figure [3](#F3){ref-type="fig"}E---control gel) and transferred to PVDF membranes. We prepared three replicate membranes. Next, each replicate was incubated with antibodies raised against rSmKI-1, KI domain, or C-terminal. Figure [3](#F3){ref-type="fig"}E reveals that anti-r*Sm*KI-1 antibodies were able to recognize the whole protein and its fragments, while anti-KI domain and anti-C-terminal antibodies are more specific to its correspondent protein fragment, although they were able to bind rSmKI-1.

![Humoral immune responses to recombinant SmKI-1 (r*Sm*KI-1) or its fragments. Sera from rSmKI-1-vaccinated (black squares), or KI domain-vaccinated (black/gray squares), or from C-terminal-vaccinated (gray squares) and ACG (black circles) mice. Mouse sera (mean ± SD, *n* = 10) were tested by ELISA to evaluate the levels of total IgG antibodies **(A)** or specific IgG1 **(B)** or IgG2c **(C)** antibodies at the indicated time points during the vaccination trial. Asterisks indicate differences detected in protein-immunized group compared to ACG (\*\*\**p* \< 0.005) and hashtag indicate differences detected in KI domain-vaccinated group compared to SmKI-1-vaccinated group (^\#^*p* \< 0.05). **(D)** ELISA plates were coated with rSmKI-1 or its fragments individually and wells were incubated with diluted serum from immunized mice. Anti-IgG from mice were used to detect antibody binding to proteins. The numbers in *X*-axis indicate the dilution factor in a logarithmic scale. Results are presented as the antibody titers (expressed by their denominators) for each group (mean ± SD, *n* = 10). An asterisk indicates differences detected among fragments-vaccinated mice and rSmKI-1-vaccinated group (\**p* \< 0.05). **(E)** Detection by Western blot of rSmKI-1 and its fragments. Lanes contain (1) rSmKI-1, (2) KI domain, and (3) C-terminal proteins. A SDS-PAGE stained with Coomassie is shown as control gel, followed by Western blotting of purified proteins probed with mouse anti-*Sm*KI-1, anti-KI domain, and anti-C-terminal polyclonal antibodies, respectively.](fimmu-09-01762-g003){#F3}

Th1 Cytokine Profile Induced by r*Sm*KI-1, Kunitz Domain, or C-Terminal Fragment Vaccination {#S3-4}
--------------------------------------------------------------------------------------------

Following vaccination with *Sm*KI-1, KI domain, or C-terminal, we measured the production of IFN-γ (Figure [4](#F4){ref-type="fig"}A), TNF-α (Figure [4](#F4){ref-type="fig"}B), IL-4, IL-5, and IL-10 (Figure [4](#F4){ref-type="fig"}C) in supernatants of spleen cells stimulated with purified proteins. In animals immunized with r*Sm*KI-1, we detected higher levels of IFN-γ (764.5 ± 228.0 pg/mL), TNF-α (1288.8 ± 172.8 pg/mL), and IL-10 (2049 ± 243.9 pg/mL) compared to control group. Similarly, KI domain- or C-terminal-immunized mice also presented greater amounts of IFN-γ (613.4 ± 221.0 or 1285.7 ± 339.0 pg/mL, respectively), TNF-α (1506.0 ± 49.0 or 1395.0 ± 309.4 pg/mL), and IL-10 (492.11 ± 161.0 or 721.83 ± 178.3 pg/mL) in comparison to control group. Th2 cytokines, IL-4, and IL-5, were produced in very low levels with no statistically significant differences detected between vaccinated and control groups. ConA or LPS were used as positive controls to confirm that splenocytes were responsive to stimuli (Figure [4](#F4){ref-type="fig"}). Spleen cells stimulated with medium alone produced no, or negligible cytokine levels (Figure [4](#F4){ref-type="fig"}). Taken together, these findings suggest that SmKI, KI domain, or C-terminal induced a Th1 type of immune response in vaccinated animals.

![Cytokine profile of splenocytes from recombinant SmKI-1 (r*Sm*KI-1), Kunitz domain, or C-terminal-vaccinated mice. Ten days after the final immunization with r*Sm*KI-1, KI domain, C-terminal, or adjuvant as control, splenocytes from five mice were isolated and assayed for their IFN-γ **(A)**, TNF-α **(B)**, and IL-10 **(C)** production (mean ± SD) in response to stimulation with purified protein (r*Sm*KI-1, KI domain, or C-terminal) or ConA/LPS or medium. Significant differences between data from protein-immunized mice \[*Sm*KI-1 + Complete Freund's Adjuvant (CFA)/Incomplete Freund's Adjuvant (IFA), KI domain + CFA/IFA, or C-terminal + CFA/IFA\] compared to adjuvant-administered (ACG) animals are denoted by \**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.005.](fimmu-09-01762-g004){#F4}

Immunization With r*Sm*KI-1 or C-Terminal Tail, but Not KI Domain Induces Protective Immunity in Mice {#S3-5}
-----------------------------------------------------------------------------------------------------

Two independent vaccination trials with similar results were conducted using C57BL/6 mice and protective immunity was evaluated 45 days after challenge with 100 *S. mansoni* cercariae. The control group received adjuvant only in phosphate buffered saline (ACG). Mice vaccinated with r*Sm*KI-1 showed 46.7% reduction in worm burden (Figure [5](#F5){ref-type="fig"}---black bars), and C-terminal fragment vaccination reduced in 27.8% of the worm burden (Figure [5](#F5){ref-type="fig"}---gridded bars), while the KI domain immunization did not induce reduction in recovered parasites (Figure [5](#F5){ref-type="fig"}---gray bars).

![Vaccination with recombinant SmKI-1 (r*Sm*KI-1) or C-terminal reduces the worm burden. Worm burden (mean ± SD) recovered from control mice injected with adjuvant versus mice immunized with rSmKI-1 (black bars) or KI domain (gridded bars) or C-terminal (gray bars) and challenged with *Schistosoma mansoni* cercariae (*n* = 10/group). Graphs represent data from one of two independent vaccine trials. Mice vaccinated with rSmKI-1 or C-terminal showed a 47 or 28% reduction in the adult worm burden, respectively, while mice vaccinated with KI domain showed no difference when compared to ACG. Asterisks indicate statistically significant differences between the protein-vaccinated mice and the control group (\*\*\**p* \< 0.005, \*\**p* \< 0.01, and \**p* \< 0.05).](fimmu-09-01762-g005){#F5}

Regarding the presence of eggs in mouse livers, vaccination with r*Sm*KI-1 reduced the number of eggs per gram of liver tissue by 36% (Figure [6](#F6){ref-type="fig"}A). A similar reduction, 38% in number of eggs, was also induced in the group vaccinated with the C-terminal. No difference was observed among KI domain-vaccinated mice or ACG. Additionally, analysis of the hepatic tissue demonstrated that *Sm*KI-1 or C-terminal vaccination reduced liver pathology. Histopathological analysis demonstrated that granuloma area was reduced by 33 or 25% in mice which received formulations containing r*Sm*KI-1 or C-terminal, respectively, when compared to mice which received adjuvant only (Figure [6](#F6){ref-type="fig"}B). For KI domain immunization, no difference to ACG immunization was observed. Figures [6](#F6){ref-type="fig"}C--F also shows representative images of granulomas from a liver section of ACG, r*Sm*KI-1, KI domain, or C-terminal vaccinated mice.

![Vaccination recombinant SmKI-1 (r*Sm*KI-1) or C-terminal reduces liver pathology in mice. **(A)** Number of eggs per gram of liver tissue (mean ± SD) of mice (*n* = 8/group). Mice vaccinated with r*Sm*KI-1 or C-terminal fragment showed 38 or 36% reduction in egg numbers, respectively. **(B)** Granuloma area (mean ± SD) in mouse liver sections. Reductions of 33 or 25% are observed after vaccination with r*Sm*KI-1 or C-terminal tail, respectively. Asterisks indicate statistically significant differences between the protein-vaccinated animals compared to the control group (\*\**p* \< 0.01). Representative images of granulomas detected in a hematoxylin and eosin-stained liver sections from a **(C)** ACG, **(D)** rSmKI-1-vaccinated, **(E)** KI domain-vaccinated, or **(F)** C-terminal-vaccinated animals. The bar represents 0.05 mm.](fimmu-09-01762-g006){#F6}

Discussion {#S4}
==========

Recently, our group demonstrated that *Sm*KI-1 is highly expressed in intravascular stages of life cycle, schistosomula, and adult. We also showed that expression of *Sm*KI-1 is essential for parasite survival inside the host, since *Sm*KI-1 siRNA suppression demonstrated a robust impact in schistosome development and survival *in vivo* ([@B10]). This protein also presents possible functions in host coagulation processes ([@B9]) and in parasite immune evasion ([@B10]). Considering that *Sm*KI-1 plays a vital role in parasite survival, we decided to evaluate its potential as vaccine candidate against schistosomiasis.

Bioinformatic analysis of *Sm*KI-1 indicated that the most dominant B cell epitopes are located in the C-terminal fragment of the protein, an observation predictive of the experimental results. Immunolocalization experiments using polyclonal anti-r*Sm*KI-1 indicated that *Sm*KI-1 is mainly present in the intestinal tract in larval stage schistosomula, although it has previously reported to be localized on the tegument in adult worms ([@B9]). The intestinal tract is made up of gastrodermis, which consists of a syncytial epithelial layer with many vacuolar compartments that project into the lumen ([@B6], [@B11]). During schistosome blood feeding, the gastrodermis is accessible to host macromolecules such as immunoglobulins ([@B26], [@B27]) which implies direct contact between the digestive epithelia and the host immune system. Gastrodermis proteins were previously tested as vaccines conferring partial protection to mice against schistosomiasis. Sm10.3 antigen and Syntenin partially reduced the worm burden and ameliorated liver pathology ([@B11], [@B12]) and the gut protease SmCB1 reduced significantly worm burden and eggs present in liver and intestine ([@B28]). In adult worms, *Sm*KI-1 was localized on the tegument, which is also a major host--parasite interface ([@B7], [@B8]). Numerous tegument antigens have been assessed as vaccine and a previous work from our group achieved a 50% protection testing the antigen Sm29 in murine model ([@B25]). Taken together, *Sm*KI-1 epitope mapping and immunolocalization of the protein provide evidence suggesting that *Sm*KI-1 would make a potential vaccine target against schistosomiasis.

In our previous study, we were able to express and purify rSmKI-1, as well as two other protein fragments: KI domain and C-terminal tail ([@B10]). Herein, these three proteins were individually used in vaccine formulation associated with Freund's adjuvant. Mice immunization with these vaccines induced high levels of specific IgG antibodies compared to adjuvant control group. Previous studies associate high levels of IgG isotypes with schistosomula death through antibody-dependent cell-mediated cytotoxicity and the activation of complement ([@B29], [@B30]). The lower levels of both IgG1 and IgG2c produced by KI-domain-immunized mice when compared to SmKI-1-immunized mice are probably related to lower protection against schistosomiasis in the previous group. Antibody production is also involved in long-term protective immunity and related to resistance to schistosomiasis reinfection ([@B31]--[@B33]). Regarding cytokine profile, supernatants of cultured splenocytes extracted from immunized mice and stimulated with correspondent purified protein yielded high levels of IFN-γ and TNF-α, indicating the development of a Th1-type of immune response. The majority of *S. mansoni* antigens tested as vaccine candidates that conferred partial protection against cercariae challenge induced a Th1-type immune response ([@B24], [@B25], [@B34], [@B35]). IFN-γ is a pro-inflammatory cytokine which augments the immune response to schistosome infection by promoting leukocyte activation ([@B24], [@B36], [@B37]). Macrophage recruitment and activation by IFN-γ is related to worm killing ([@B38]) and, together with TNF-α, this cytokine increases the levels of nitric oxide produced by these macrophages in the protective immune response against *S. mansoni* ([@B39]). Further, IFN-γ depletion renders mice unable to develop effective defense against schistosome infection ([@B39], [@B40]). Previous studies demonstrate that serine protease inhibitors, when tested as vaccine, are able to induce notable changes in immunological response. The *Toxoplasma gondii* serine protease inhibitor TgPI-1 elicited high titers of IgG antibodies and induced a mixed Th1/Th2 immunological response, with significant production of IFN-γ, when evaluated as a vaccine candidate ([@B41], [@B42]). Another serine protease inhibitor present in the intracellular bacteria *Brucella abortus*, the protein Omp-19, when evaluated as a vaccine candidate, elicited a Th1 immunological response when administrated intraperitoneally, and a mixed Th1/Th17 immunological profile but when administrated orally ([@B43], [@B44]). Finally, *Ancylostoma ceylanicum* Kunitz-type inhibitor (AceKI), also elicited significant titers of IgG in a murine model ([@B45]).

Despite high levels of pro-inflammatory cytokines, significant amounts of IL-10 were also produced in experimental-vaccinated groups. IL-10 is an important regulatory cytokine, essential to modulation of the immune response triggered by *S. mansoni* infection ([@B37], [@B46], [@B47]). This cytokine possibly regulates Th2-type response, reducing inflammation in liver pathology ([@B46]). Consistent with that, we detected reduced liver pathology in *Sm*KI-vaccinated mice, group of animals with enhanced IL-10 production. Similarly, the *T. gondii* serine protease inhibitor TgPI-1, when formulated with Alum and CpG-ODN, also induced the production of high levels of IL-10 in a murine model of vaccination ([@B42]).

After describing the immune response generated by vaccinated mice, we next investigated whether rSmKI-1 or its fragments could induce protection in a murine model of *S. mansoni* infection. For each protein, two independent experiments were performed. r*Sm*KI-1 conferred a partial protection to infection, resulting in 47% reduction in worm burden. Vaccination experiments using C-terminal region of *Sm*KI-1 resulted in 28% reduction in worm burden, while KI domain trial did not engender protective immunity. Immunization with *Sm*KI-1 or its C-terminal tail also ameliorated liver pathology, since their groups presented 36 and 38% reduction in eggs trapped in liver, respectively. The granuloma area around the eggs was also reduced, 33% upon *Sm*KI-1 vaccination and 25% following C-terminal immunization. Comparatively, the *Boophilus microplus* trypsin inhibitors, containing one or two kunitz proteins, were also able to induce significant protection levels in immunized *Bos indicus*, reaching almost 70% in cattle tick reduction ([@B48]). Also, the recombinant serine protease inhibitors TgPI-1, Omp-19, and AceKI were able to induce significant protection levels in murine models of *T. gondii, B. abortus*, and *A. ceylanicum* infections, respectively ([@B42]--[@B45]).

Previous bioinformatics analysis predicted the C-terminal as a region of unstructured amino acid residues with no similarity with other proteins deposited in the databanks ([@B10]). This fragment calls our attention due to epitope prediction which revealed a high probability of recognition by MHC II alleles and significant B cell linear epitopes. Epitope prediction findings seem to corroborate to experimental data, since the best protection results were found in *Sm*KI-1 fragment with higher probability for B and T cell epitopes. The KI domain is highly conserved among species and possesses the protease inhibitor function of *Sm*KI-1 ([@B10]). Ranasinghe et al. reported no potential cross-reactivity among SmKI-1 and human TFPI, another Kunitz-type protease inhibitor ([@B49]). High identity between host and parasite proteins can be a problem in vaccine development. Despite high antibody titers and the induction of cytokine production, vaccination with KI domain failed to protect mice from schistosome infection, demonstrating no apparent correlation between the anti-KI immune response generated and vaccine protective efficacy.

In summary, the data presented here demonstrate that r*Sm*KI-1 formulated with Freund's adjuvant generates partial protection against schistosome infection in mice. The protein region correspondent to the C-terminal tail seems to be the region mainly responsible for host immune stimulation, since it seems to have the most important epitopes and generates partial protection against schistosome infection, while the KI domain failed to do so. Taken together, these results support further studies in which *Sm*KI-1, or a fragment thereof, could be optimized and used as a promising vaccine candidate to control schistosomiasis.
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